Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2006

View Archived Issues

Novel pathway involved in ADPKD identified / News in Context

New class of PG transporter inhibitors presented

Novel ligand-antibody protein specifically enhances cell lysis in MM

ViroPharma licenses right to develop novel therapeutic for CDAD

Zenyth enters licensing agreement with Ludwig Institute for Cancer Research

Oragenics: business plan for 2006

Callisto to study atiprimod in carcinoid cancer patients

Lucentis BLA for wet AMD granted priority review

Medivation updates progress of Dimebon for Alzheimer's and Huntington's disease

FDA accepts Genasense NDA for relapsed or refractory CLL

Invitrogen agreement supports DelSite's development of avian H5 flu nasal vaccine

RK-0202 set to enter phase III for oral mucositis

Treatment begins in phase III study of Delcath system

Pfizer acquires sanofi-aventis' rights to Exubera

Enzo cleared to begin HIV study of Stealth Vector HGTV43 gene construct

Albany Molecular Research completes acquisition of ComGenex

Astellas acquires Dynogen research facility

Novel compounds claimed for therapy of cardiovascular disorders in recent patent literature

Novel agents for treating diabetes and related complications disclosed in recent patents

BLA submission for Cimzia in Crohn's disease

FDA approval for Erbitux in head and neck cancer

sNDA seeks approval of Byetta for use with TZDs

Tygacil recommended for approval in Europe

Alcon withdraws European submission for Retaane

Tetracaine oral gel may be beneficial for relief of mucositis-related pain / News in Context

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...